Shorter TB Regimen Misses the Mark
Shorter high-dose rifampicin regimens proved safe for treating pulmonary tuberculosis (TB), but failed to demonstrate noninferiority compared with the standard 6-month regimen, a phase III trial found. For the primary efficacy outcome, an absolute 6.3% more adults receiving a 4-month regimen that included the highest dose of rifampicin had an unfavorable outcome at 12 to […]
Zaire Ebola Vaccines Produce Antibody Responses as Early as 14 Days
Three vaccine regimens for Zaire Ebola virus disease (EVD) produced antibody responses in adults and children, according to the results of two randomized trials conducted in West Africa. At 12 months, 41% of adults and 78% of children had a response to the Ad26-MVA regimen (Ad26.ZEBOV followed by MVA-BN-Filo 56 days later), 76% and 87% […]
On-Demand PrEP Surpasses Daily Use Among Chinese MSM
Event-driven HIV prevention regimens appeared to have a better protective effect, and a better trend of medication adherence, than daily regimens in a real-world setting among men who have sex with men (MSM), a researcher said. In four cities in China, MSM who opted for event-driven pre-exposure prophylaxis (PrEP) — that is, that they only […]